Domainex share their latest updates in recent newsletter including:
- Receiving a King's Award for Enterprise
- Expansion plans in UK and US
- The launch of new Cryo-EM and Flow Cytometry services
- Latest recruits
News
Our August eNews is here: 'Embracing Change and Unlocking Opportunities in the Evolving Life Science Industry'
✅ This month's overview from Tony Jones, CEO, One Nucleus
✅ Be at Your Best with One Nucleus Events
✅ ON Helix 2023 - When do Good Neighbours become Good Business Partners?
✅ One Nucleus wins Gold Award for Green Impact
✅ The Evolving Role of Online Innovation Workshops via One Nucleus
Read it here: https://bit.ly/3KMjntR
OMass Therapeutics Expands Leadership Team with Two New Appointments
- Appointment of two senior executives in newly created roles
- Peter Phillips M.D., Ph.D. joins as Senior Vice President of Clinical Development and Julia Sampson Ph.D. joins as Vice President of Non-clinical Development
Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions and advances their vision to become the global market leader.
Check out a roundup of news, updates and highlights from ValiRx this month, including their attendance at ON Helix 2023: ValiRx News Roundup - August 2023
"ValiRx and Inaphaea teams attend On Helix
AMSBIO announce a new range of pre-made Nano-Lantern lentivirus products that utilize a proprietary lentiviral vector system to enable highly sensitive and precise in vivo luminescence imaging.
This cutting-edge Nano-Lantern lentivirus technology, which consists of an enhanced Renilla-Luciferase connected to an Orange Fluorescent protein (OFP), represents a significant improvement over previous methods and is poised to revolutionize many in vivo imaging applications.
Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
The University of Leicester has joined forces with Cambridge-based Isogenica to develop new immunotherapies – a process where the patient’s immune system is helped to fight cancer – which will be tested on a ‘virtual patient’.
Alexion, AstraZeneca’s rare disease subsidiary, is acquiring a portfolio of preclinical gene therapy programs from Pfizer. The deal will bring a number of novel adeno-associated virus (AAV) capsids to Alexion and help build on AstraZeneca’s capabilities in genomic medicine.